Celecoxib in Postoperative Analgesia for Radius Fracture Surgery
Primary Purpose
Pain, Postoperative
Status
Recruiting
Phase
Phase 4
Locations
Czechia
Study Type
Interventional
Intervention
Celecoxib 100 mg
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Pain, Postoperative focused on measuring Postoperative pain, Distal radius fracture, Osteosynthesis, Celecoxib
Eligibility Criteria
Inclusion Criteria:
- Patients scheduled for osteosynthesis of distal radius fracture
Exclusion Criteria:
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
- Patients who have demonstrated allergic-type reactions to sulfonamides.
- Inability to understand the questionnaire
Sites / Locations
- Jiří MálekRecruiting
- Faculty Hospital Kralovske VinohradyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Celecoxib
Placebo
Arm Description
Celecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
A placebo pill provided by a hospital pharmacy will be administered in the day of surgery at 6 in the morning and 6 in the afternoon for 3 days.
Outcomes
Primary Outcome Measures
Postoperative pain intensity
Intensity of pain measured by numeric rating scale (NRS) 0-10
Secondary Outcome Measures
Number of piritramid injection
Piritramid 15 mg intramuscularly will be administered if numeric rating scale (NRS 0-10) of pain is NRS>4
Side effects of treatment
Incidence of stomach pain, heartburn, gas, diarrhea, constipation, nausea, vomiting, dizziness, others
Full Information
NCT ID
NCT05288374
First Posted
March 10, 2022
Last Updated
September 2, 2023
Sponsor
Charles University, Czech Republic
Collaborators
Faculty Hospital Kralovske Vinohrady
1. Study Identification
Unique Protocol Identification Number
NCT05288374
Brief Title
Celecoxib in Postoperative Analgesia for Radius Fracture Surgery
Official Title
Celecoxib for Treatment of Postoperative Pain After Osteosynthesis of Distal Radius Fracture
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 10, 2022 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Charles University, Czech Republic
Collaborators
Faculty Hospital Kralovske Vinohrady
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients scheduled for elective osteosynthesis of the distal radius will be randomized to receive celecoxib 100 mg orally (PO) at 6 in the morning before surgery and every 12 hours for 2 days thereafter, or a placebo pill in the same regimen. After surgery under general anaesthesia, they will receive paracetamol 1 g intravenously (IV) every 6 hours and if pain intensity is greater than 4 on a numeric rating scale (NRS) of 0-10, piritramid 15 mg intramuscularly (IM) will be administered. Pain intensity, piritramid consumption and side effects of treatment will be recorded in a questionnaire for 2 days.
Detailed Description
A prospective single-blinded randomized study will be performed in patients of the Orthopaedic Clinic of the 3rd Medical Faculty of Charles University (3LF UK) and the Faculty Hospital Kralovske Vinohrady (FHKV) scheduled for elective osteosynthesis of the distal radius. The expected number of participants is 25 in each arm of the study. They will be randomized by envelope method into an non-steroidal analgesic (NSA) group, which will receive celecoxib at 6 in the morning before surgery, and a C group, which will receive a placebo pill prepared by the hospital pharmacy. General anesthesia will be performed in both groups in the standard way using propofol, sufentanil and sevoflurane 1 minimal alveolar concentration (MAC) with air and oxygen at 40% concentration. At the end of surgery, each patient will be given paracetamol 1 g intravenously (IV) and ondansetron 4 mg IV. Pain intensity after surgery will be measured on a numerical rating scale (NRS) 0-10. For postoperative analgesia, both groups will receive paracetamol 1 g IV. every 6 hours, and for NRS>4 pain intensity, piritramid 15 mg intramuscularly (IM). The NSA group will receive celecoxib 100 mg orally (PO) at 6 in the morning and 6 in the afternoon, and group C will receive placebo at the same interval.
Parameters to be monitored will be postoperative pain intensity for the primary objective, and opioid piritramid consumption and side effects of the treatment for the secondary objectives. NRS, number of doses of piritramid and side effects will be recorded in a coded questionnaire.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative
Keywords
Postoperative pain, Distal radius fracture, Osteosynthesis, Celecoxib
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Celecoxib 100 mg orally on the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
Masking
Participant
Masking Description
Placebo pill provided by a hospital pharmacy will be administered orally on the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Celecoxib
Arm Type
Experimental
Arm Description
Celecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A placebo pill provided by a hospital pharmacy will be administered in the day of surgery at 6 in the morning and 6 in the afternoon for 3 days.
Intervention Type
Drug
Intervention Name(s)
Celecoxib 100 mg
Other Intervention Name(s)
Celebrex 100 mg
Intervention Description
Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo pill
Intervention Description
Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
Primary Outcome Measure Information:
Title
Postoperative pain intensity
Description
Intensity of pain measured by numeric rating scale (NRS) 0-10
Time Frame
up to 2 days
Secondary Outcome Measure Information:
Title
Number of piritramid injection
Description
Piritramid 15 mg intramuscularly will be administered if numeric rating scale (NRS 0-10) of pain is NRS>4
Time Frame
3 days
Title
Side effects of treatment
Description
Incidence of stomach pain, heartburn, gas, diarrhea, constipation, nausea, vomiting, dizziness, others
Time Frame
3 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients scheduled for osteosynthesis of distal radius fracture
Exclusion Criteria:
Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
Patients who have demonstrated allergic-type reactions to sulfonamides.
Inability to understand the questionnaire
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiří Málek, MD
Phone
+420737673267
Email
malekj@fnkv.cz
First Name & Middle Initial & Last Name or Official Title & Degree
Alice Kurzova, MD
Phone
+420604933660
Email
aliku@seznam.cz
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jiří Málek, MD
Organizational Affiliation
3rd Medical Faculty of Charles University and Faculty Hospital Kralovske Vinohrady
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jiří Málek
City
Praha 3
ZIP/Postal Code
13000
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiří Málek, M.D.
Phone
+420737673267
Email
malekj@fnkv.cz
First Name & Middle Initial & Last Name & Degree
Jiří Málek
Phone
+420267162461
Email
malekj@fnkv.cz
First Name & Middle Initial & Last Name & Degree
Vladimir Pacovsky, M.D.
First Name & Middle Initial & Last Name & Degree
Alice Kurzova, M.D.
Facility Name
Faculty Hospital Kralovske Vinohrady
City
Praha
ZIP/Postal Code
100 00
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiri Malek, M.D.
First Name & Middle Initial & Last Name & Degree
Alice Kurzova, M.D.
12. IPD Sharing Statement
Learn more about this trial
Celecoxib in Postoperative Analgesia for Radius Fracture Surgery
We'll reach out to this number within 24 hrs